GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuCell Corp (NAS:ICCC) » Definitions » Degree of Operating Leverage

ICCC (ImmuCell) Degree of Operating Leverage : -3.80 (As of Mar. 2025)


View and export this data going back to 1987. Start your Free Trial

What is ImmuCell Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. ImmuCell's Degree of Operating Leverage for the quarter that ended in Mar. 2025 was -3.80. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for ImmuCell's Degree of Operating Leverage or its related term are showing as below:

ICCC's Degree of Operating Leverage is ranked better than
85.36% of 881 companies
in the Biotechnology industry
Industry Median: -0.02 vs ICCC: -3.80

ImmuCell Degree of Operating Leverage Historical Data

The historical data trend for ImmuCell's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuCell Degree of Operating Leverage Chart

ImmuCell Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.18 -5.41 289.85 -25.23 -1.35

ImmuCell Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.96 -0.79 -0.97 -1.35 -3.80

Competitive Comparison of ImmuCell's Degree of Operating Leverage

For the Biotechnology subindustry, ImmuCell's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ImmuCell's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuCell's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where ImmuCell's Degree of Operating Leverage falls into.


;
;

ImmuCell Degree of Operating Leverage Calculation

ImmuCell's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( 0.257 (Mar. 2025) / -3.391 (Mar. 2024) - 1 )/( 27.303 (Mar. 2025) / 21.284 (Mar. 2024) - 1 )
=-1.0758/0.2828
=-3.80***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


ImmuCell  (NAS:ICCC) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


ImmuCell Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of ImmuCell's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


ImmuCell Business Description

Industry
Traded in Other Exchanges
N/A
Address
56 Evergreen Drive, Portland, ME, USA, 04103
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
Executives
Bryan K. Gathagan director 56 EVERGREEN DRIVE, PORTLAND ME 04103
David Cunningham director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Gloria F Basse director 56 EVERGREEN DRIVE, PORTLAND ME 04103
David Scott Tomsche director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Steven T. Rosgen director C/O IMMUCELL CORPORATION, 56 EVERGREEN DR., PORTLAND ME 04103
Norman H Pessin other: See Explanation of Responses C/O LEVY, HARKINS & CO., INC., 366 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10017
Brian L. Pessin other: See Explanation of Responses 310 EAST 75TH STREET, APT. 2A, NEW YORK NY 10021
Joseph H Crabb director, officer: Vice President and CSO IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Elizabeth Luttrell Williams officer: Vice Pres. of Mfg Operations C/O IMMUCELL CORPORATION, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Jonathan E Rothschild director, 10 percent owner C/O IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Linda Rhodes director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Paul R Wainman director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Michael F Brigham director, officer: President and CEO IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Bobbi Jo Kunde other: Director of Sales and Marketin 56 EVERGREEN DRIVE, PORTLAND ME 04103
Robert C Bruce director 56 EVERGREEN DRIVE, PORTLAND ME 04103